Economic Benefit-Cost Analysis of Select Secondary Prevention Interventions in LMIC

Global Heart

Volumn 10, Issue 4, 2015, Pages 319-321

  Nugent, Rachel ^a   Brouwer, Elizabeth ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; COST BENEFIT ANALYSIS; HIGH RISK POPULATION; HUMAN; MORTALITY; NON COMMUNICABLE DISEASE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; SECONDARY PREVENTION; SUSTAINABLE DEVELOPMENT; TAX; TOBACCO USE; UNITED STATES; WORLD HEALTH ORGANIZATION; ADULT; AGED; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DEVELOPING COUNTRY; ECONOMICS; LIFE EXPECTANCY; MIDDLE AGED; MOTIVATION; PREMATURE MORTALITY; PREVENTION AND CONTROL; SMOKING;

ADULT; AGED; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; GOALS; HUMANS; LIFE EXPECTANCY; MIDDLE AGED; MORTALITY, PREMATURE; SECONDARY PREVENTION; SMOKING; TAXES;

EID: 84984832228     PISSN: 22118160     EISSN: 22118179     Source Type: Journal    
DOI: 10.1016/j.gheart.2015.09.002     Document Type: Review

References (15)

1. 1 WHO. NCD Global Monitoring Framework. 2012, World Health Organization, Geneva, Switzerland.
2. 2 WHO. Draft Comprehensive Global Monitoring Framework and Targets for the Prevention and Control of noncommunicable Diseases. 2013, World Health Organization, Geneva, Switzerland.
3. 3 Lim, S.S., Vos, T., Flaxman, A.D., et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380 (2012), 2224–2260.
4. 4 Jamison, D.T., Breman, J., Measham, A., Alleyne, G., Claeson, M., Evans, D., (eds.) Disease Control Priorities in Developing Countries, 2nd edition, 2006, World Bank, Washington, DC.
5. 5 Yusuf, S., Islam, S., Chow, C.K., et al., for the PURE Study Investigators. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 378 (2011), 1231–1243.
6. 6 Kotseva, K., Wood, D., De Backer, G., et al., for the EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 373 (2009), 929–940.
7. 7 Yusuf, S., Two decades of progress in preventing vascular disease. Lancet 360 (2002), 2–3.
8. 8 WHO. From Burden to 'Best Buys': Reducing the Economic Impact of Non-Communicable Diseases in Low- and Middle-Income Countries. 2011, World Health Organization, World Economic Forum, Geneva, Switzerland.
9. 9 Jha, P., Nugent, R., Verguet, S., Bloom, D., Hum, R., Chronic Disease Prevention and Control. Global Problems, Smart Solutions: Costs and Benefits, 2013, Cambridge University Press, Cambridge.
10. 10 Jha, P., Peto, R., Global effects of smoking, of quitting, and of taxing tobacco. N Engl J Med 370 (2014), 60–68.
11. 11 Kontis, V., Mathers, C.D., Rehm, J., et al. Contribution of six risk factors to achieving the 25 × 25 non-communicable disease mortality reduction target: a modelling study. Lancet 384 (2014), 427–437.
12. 12 WHO. Global Health Estimates Summary Tables: Projection of Deaths by Cause, Age, and Sex. July 2013 edition, 2013, World Health Organization, Geneva, Switzerland.
13. 13 WHO. World Health Organization: Prevalence of Tobacco Use Among Adults and Adolescents. 2014 Available at: http://gamapserver.who.int/gho/interactive_charts/tobacco/use/atlas.html Accessed December 5, 2014.
14. 14 WHO. WHO Report on the Global Tobacco Epidemic, 2013: Enforcing Bans on Tobacco Advertising, Promotion and Sponsorship. 2013, World Health Organization, Geneva, Switzerland.
15. 15 Asaria, P., Chisholm, D., Mathers, C., Ezzati, M., Beaglehole, R., Chronic disease prevention: health effects and financial costs of strategies to reduce salt intake and control tobacco use. Lancet 370 (2007), 2044–2053.